A cheap antidepressant reduced the need for hospitalization among high-risk adults with COVID-19 in a study hunting for existing drugs that could be...
A cheap antidepressant reduced the need for hospitalization among high-risk adults with COVID-19 in a study hunting for existing drugs that could be repurposed to treat coronavirus.
“If WHO recommends this, you will see it widely taken up,” said study co-author Dr. Edward Mills of McMaster University in Hamilton, Ontario, adding that many poor nations have the drug readily available. “We hope it will lead to a lot of lives saved.” In the group that took the drug, 11% needed hospitalization or an extended ER stay, compared to 16% of those on dummy pills.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Covid-19: Record case rates in Wales and long Covid study begins in ScotlandFive things you need to know about the coronavirus pandemic this Tuesday evening.
Les mer »
Covid-19 vaccine rates for kids echo regional disparities, worrying doctorsWhether children receive a dose of a Covid-19 vaccine often depends on where they call home.
Les mer »
How COVID-19 in kids compares to the flu, other viruses in childrenCOVID-19 isn’t the only viral disease children are catching this year. Influenza, which sends thousands of children to the hospital each season, is predicted to ramp up in the coming months.
Les mer »
CDC Extends COVID-19 Rules For Cruises Through Mid-JanuaryThe health and safety protocols put in place due to the coronavirus pandemic will then become voluntary, the agency said.
Les mer »
COVID-19 live updates: FDA panel hours away from vote on Pfizer vaccine for kidsAn independent FDA advisory panel will debate and vote on whether to authorize the Pfizer vaccine for children ages 5 to 11. The nonbinding vote is expected between 4:30 p.m. and 5 p.m. ET today.
Les mer »
FDA's independent vaccine committee meets to discuss Pfizer's Covid-19 vaccine for young kidsThe US Food and Drug Administration's independent vaccine advisory committee meets Tuesday to discuss if the Pfizer/BioNTech Covid-19 vaccine should be authorized for children ages 5 to 11.
Les mer »